TriangleNCT00007345 · OUTCOME
Median Number of Cycles of Depsipeptide Administered
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Cycles per patient
- Interval / dispersion
- Full Range
- Time frame
- 83 cycles (i.e., each cycle is 21 days)
What was measured
Participants were administered Depsipeptide and cycles (each cycle is 21 days) were monitored from the prescribed dose or higher to determine reductions (if needed) to maintain tolerability.
Groups in this outcome
Peripheral T-cell Lymphoma (PTCL)
Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\^2 and at 17.5 mg/m\^2 on days 1, 8, and 15 of a 28 day cycle.
Cutaneous T-cell Lymphoma (CTCL)
Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\^2 and at 17.5 mg/m\^2 on days 1, 8, and 15 of a 28 day cycle.
| Group | Source count |
|---|---|
| Peripheral T-cell Lymphoma (PTCL) | 47 |
| Cutaneous T-cell Lymphoma (CTCL) | 84 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Peripheral T-cell Lymphoma (PTCL) | 3 | Not reported | 1 | 83 | Not reported |
| Cutaneous T-cell Lymphoma (CTCL) | 4.5 | Not reported | 1 | 79 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1
- upper Limit
- 83
- value
- 3
- group Id
- OG001
- lower Limit
- 1
- upper Limit
- 79
- value
- 4.5
- denoms
- counts
- group Id
- OG000
- value
- 47
- group Id
- OG001
- value
- 84
- units
- Participants
- description
- Participants were administered Depsipeptide and cycles (each cycle is 21 days) were monitored from the prescribed dose or higher to determine reductions (if needed) to maintain tolerability.
- dispersion Type
- Full Range
- groups
- description
- Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\^2 and at 17.5 mg/m\^2 on days 1, 8, and 15 of a 28 day cycle.
- id
- OG000
- title
- Peripheral T-cell Lymphoma (PTCL)
- description
- Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\^2 and at 17.5 mg/m\^2 on days 1, 8, and 15 of a 28 day cycle.
- id
- OG001
- title
- Cutaneous T-cell Lymphoma (CTCL)
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- 83 cycles (i.e., each cycle is 21 days)
- title
- Median Number of Cycles of Depsipeptide Administered
- type
- SECONDARY
- unit Of Measure
- Cycles per patient
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice